Clients trust Mark Remus to solve their patent disputes quickly, efficiently, and strategically. He has served as lead counsel on numerous patent infringement litigation matters, and he has successfully represented clients in jury trials, bench trials, and appeals to the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court. Intellectual Asset Management (IAM) magazine writes that Mark is “[a]lways one of the best lawyers in the courtroom, he has an even temperament for litigation and is precise in everything he does,” calling him “quite a force to be reckoned with.” Clients recognize Mark for being “always well-prepared and conscientious” and “tough when the situation requires it.”
Mark has extensive experience with pharmaceutical litigation under the Hatch-Waxman Act. He has advised clients on a wide range of drug products and technologies, including new chemical entities, complex formulations, polymorphs, methods of treatment and extended release formulations. Mark is also experienced in FDA practice and strategy related to generic pharmaceutical products, including controlled correspondence, citizen petitions, suitability petitions and labeling carve-outs.
Mark also has experience with a wide range of technologies, including LCD panels, fiber optic networks, wind turbines, electrical connectors, medical devices, pharmaceutical products, oil drilling, and mechanical devices.
Mark consistently has been named by publications and in lists that honor attorney achievement, including the IAM Patent 1000 (2021) and Managing Intellectual Property's Expert Guides: Guide to the World's Leading Patent Law Practitioners (2020). Mark has also been recognized as a Leading Life Sciences Lawyer by LMG Life Sciences (2021).
Prior to joining Crowell & Moring, Mark was a shareholder at Brinks Gilson & Lione.